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Background: Without doubt, natural products have been, and still are, the cornerstone of the health care
armamentarium. Of all natural sources, the marine environment is clearly the last great frontier for pharmaceutical
and medical research.
Methods: This work progresses in the direction of identifying component(s) from the Mediterranean sponge,
Spongia officinalis with pharmacological activities. In the present study we investigated the efficacy of methanol
extract and its semi-purified fractions (F2, F3) from Spongia officinalis for their in vivo anti-inflammatory activity using
the carrageenan-induced paw edema in rats and their in vitro antiproliferative effects by their potential cytotoxic
activity using the MTT colorimetric method and clonogenic inhibition against three human cancer cell lines (A549,
lung cell carcinoma, HCT15, colon cell carcinoma and MCF7, breast adenocarcinoma).
Results: The fractions F2 and F3 showed interesting anti-inflammatory and antiproliferative activities in a dose
dependent manner.
Conclusions: The present study indicates that the methanolic extrac and its fractions from Spongia officinalis are a
significant source of compounds with the antiproliferative and anti-inflammatory activities, and this may be useful
for developing potential chemopreventive substances.
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A variety of ingredients of traditional medicines and
herbs are being widely investigated in several parts of the
world to analyze their potential as therapeutic agents
[1-3]. Since the few last decades, marine environment
have been recognized to be a rich sources of bioactive
metabolites with varied biological and pharmacological
activities [4,5]. The most interesting phyla with respect
to pharmacological active marine compounds include
bacteria, fungi, algae, soft corals and gorgonians, sea* Correspondence: afefd@yahoo.com
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reproduction in any medium, provided the orhares and nudibranchs, bryozoans, tunicates and espe-
cially sponges [6]. Marine sponges have been considered
as a gold mine during the past few decades with respect
to the diversity of their secondary metabolites and con-
tinue to provide novel natural products with a remark-
able chemical diversity. At present, there are a number
of compounds from marine origin which are under in-
vestigation and/or are being developed as new pharma-
ceuticals on anticancer therapies [7,8]. A number of
compounds possess antispasmodic, antimalarial, antifun-
gal, antifouling, insecticidal, antiviral [7], antibacterial [9]
and anti-inflammatory activities [10]. The objective of
the present study was to evaluate the potency of metha-
nol extract and its semi-purified fractions (F2, F3) from
Spongia officinalis for inhibiting inflammation induced
by carrageenan and for growth and clonogenic inhibiting
of three human cancer cell lines A549, HCT15 andtd. This is an Open Access article distributed under the terms of the Creative
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interesting and potentially useful pharmacological
activities.Materials and methods
Sample collection and preparation of the methanol
extract
The marine sponge, Spongia officinalis was collected
from the Mediterranean Sea, in various areas of the
coastal region of Monastir (Tunisia), in July 2010, at a
depth between 2 and 5 meters. The collected samples
were cleaned by rising with sea water and distilled water
and transported in cool box to the laboratory where they
are kept in a freezer (−20°C). Identification of specimen
was carried out in the National Institute of Marine
Sciences and Technologies, Salamboo, Tunisia.
The samples were defrosted, macerated in distilled
water and then air dried at 30°C and finely powdered.
600 g of finely powdered sponge material were packed in
small bags (5x10 cm) of Whatman filter paper No. 1 and
all bags were sealed and soaked in a methanol bath three
times, steeping for 48 h. The methanol extracts were
combined and evaporated under vacuum at low
temperature (<40°C) and then stored at −20°C until use.Purification of the methanol extract
In order to localize the active fraction, methanol ex-
tract of Spongia officinalis was purified, using C18 car-
tridges (Sep-pack, Supelco), by gradient elution with
methanol–water mixture (0%, 50% and 80% methanol)
to give 3 fractions (F1, F2 and F3). Methanol solvent
was removed from fractions recuperated using rotating
evaporator at 35°C and distilled water was then added
to the residues and the aqueous phases were lyophi-
lized. The powdered fractions were stored at −20°C
until use.
Methanol extract, F2 and F3 fractions were diluted to
the desired final concentration immediately prior
manipulation.Animals
For the anti-inflammatory evaluation of the methanol ex-
tract and its semi-purified fractions (F2, F3), adult Wistar
rats (150-180 g) of both sex, provided from Pasteur insti-
tute (Tunis, Tunisia) were used. All animals were fed a
standard diet ad libitum and allowed free access to
drinking water. Animals fasted overnight before any
experiments. Housing conditions and in vivo experi-
ments were approved according to the guidelines estab-
lished by the European Union on Animal care (CEE
Council 86/609) [11].Carrageenan induced rat paw edema
The anti-inflammatory activity of our extract and
fractions on carrageenan-induced paw edema was deter-
mined according to Winter et al. [12]. The animals were
divided into three groups consisting of 6 rats each. The
control group received 2.5 ml/kg intraperitoneally (i.p.)
of saline solution, the standard groups received
Acetylsalicylate of Lysine (ASL) (300 mg/kg) (i.p.) and
the test group received the methanol extract of Spongia
officinalis (25, 50 and 100 mg/kg) and its semi-purified
fractions (F2, F3) at 50 mg/kg (i.p.). 30 min after intra-
peritoneal administration of different substances, 0.05 ml
of 1% carrageenan suspension was injected to all animals
in the left hind paw. The paw volume up to the tibiotar-
sal articulation was measured using Plethysmometer
(model 7150, Ugo Basile, Italy). The measures were
determined at 0 h (V0) (before carrageenan injection)
and 1, 3 and 5 h later (VT). The volume of paw swelling
was determined for each rat and the difference between
VT and V0 was taken as the edema volume. The percen-
tages of inhibition were calculated according to the fol-
lowing formula:
% inhibition ¼ VT  V0ð Þcontrol  VTV0ð Þtreatedgroup
 VT  V0ð Þcontrol  100
Cell culture
The human tumor cell lines A549 (lung cell carcinoma),
HCT15 (colon cell carcinoma) and MCF7 (breast adeno-
carcinoma) were obtained from the American Type Cul-
ture Collection (ATCC, Manassas, VA). Cells were
routinely grown with DMEM supplemented with 10%
fetal calf serum and 1% penicillin/streptomycin, all
obtained from Biochrom AG (Berlin, Germany). They
were grown on Flasks (Nunc, Denmark) at 37°C in a
humidified atmosphere containing 5% CO2. Cells were
replicated every 4–5 days and the medium changed once
in-between.
Viability assay
The potential effects on cell viability were investigated
according to previously reported conditions [13,14],
using the MTT assay [3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyl tetrazolium bromide, Sigma-Aldrich Chimie,
Saint-Quentin-Fallavier, France] as an indicator of meta-
bolically active cells [15].
Known number of A549, HCT15 or MCF7 cells (103)
were transferred into 96-well plates (Nunc, Denmark) in
a volume of 200 μl of culture medium and incubated for
24 h before addition of test compounds. Cells were then
exposed for 24 h at 37°C to known concentrations of the
methanol extract or fractions to be tested. After drug ex-
posure, the cells were washed with phosphate-buffered
Table 1 Anti-inflammatory effect of the intraperitoneal administration of methanol extract and its semi-purified
fractions (F2-F3) of Spongia officinalis in Carrageenan-induced rat paw edema test
Treatment Dose (mg/kg) Edema (10-2ml) Edema inhibition (%)
1h 3h 5h 1h 3h 5h
1h 3h 5h 1h 3h 5h
Control - 20.08±6.5 60.49±1.3 59.99±0.8 - - -
Methanol extract 25 17.46±5.1ns 34.78±5.3** 40.49±6.17** 13.04 42.5 32.5
50 16.02±0.78* 28.61±1.29** 32.99±1.26** 20.17 52.7 45
100 16.33±5.2* 23.16±1,14** 26.87±1.16** 18.67 61.71 55.20
Fraction F2 50 17.12±1.37ns 25.37±0.6** 29.12±4.17** 14.74 58.05 51.45
Fraction F3 50 13.5±2.9** 16.42±2.5** 21.7±3.55** 32.76 72.85 63.82
ASL (Reference drug) 300 13.71±3.27** 22.80±0.8** 22.83±4.12** 31.72 62.3 61.94
Values are expressed as mean±s.e.m. *P<0.01, **P<0.001, ns: not significant. n=6 animals.
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a further 48 h, then the culture medium was removed
and 200 μl of MTT reagent (diluted in culture medium,
0.5 mg/ml) was added. Following incubation for 4 h, the
MTT/medium was removed and DMSO (200 μl) was
added to dissolve the formazan crystals. Absorbance of
the colored solution was measured on a microplate
photometre (Bio-Tek Instruments) using a test wave-
length of 570 nm and a reference wavelength of 630 nm.
Results were evaluated by comparing the absorbance of
the treated cells with the absorbance of wells containing
cell treated by the solvent control. Conventionally, cell
viability was estimated to be 100% in the solvent control.
All experiments were performed at least twice in tripli-
cate. The concentration of substance required for 50%
growth inhibition (IC50) was estimated according to the
method described by Dellai [5].Clonogenic inhibition assay
The clonogenic inhibition assay was performed as
described previously by Nicolas et al. [16] with some
modifications. Known number of A549, HCT15 or
MCF7 cells (2.104) were transferred into six-well plates
(Becton Dickinson Labware, USA) in a volume of 2 ml
of culture medium and incubated for 24 h before
addition of test compounds. Cells were then exposedTable 2 In vitro growth inhibitory activity of the semi-
purified fractions, F2 and F3, of Spongia officinalis:
against the three human tumor cell lines A549 (lung cell
carcinoma), HCT15 (colon cell carcinoma) and MCF7
(breast adenocarcinoma)
IC50 (μg/ml)
Fractions A549 HCT15 MCF7
F2 fraction 1225 - 980
F3 fraction 231 212.5 72
IC50: 50 percent inhibition of cell growth.for 24 h at 37°C to known concentrations of the
compound to be tested. After drug exposure, the
cells were washed with phosphate-buffered saline and
subsequently re-plated in appropriate dilution in trip-
licate to assess clonogenic ability. After incubation
for 14 days, each plate was stained with crystal violet
and colonies were counted with a “colony counter
pen”. The surviving fraction was calculated as the
ratio of the number of colonies formed after treat-
ment to the product of the number of cells plated
and the plating efficiency. The IC50 value is the con-
centration of the drug which is capable of bringing
about 50% inhibition of colony formation.Statistical analysis
For all our experiments, a one-way ANOVA was used to
analyze the differences between groups, followed by a
Duncan’s test with a threshold of significance of p< 0.01
and p< 0.001 to detect specific differences, using a stat-
istical software package (STATISTICA edition 99Figure 1 Effect of the semi purified fraction F2 from Spongia
officinalis, on cellular growth against three human tumor cell
lines (A549, lung cell carcinoma, HCT15, colon cell carcinoma
and MCF7, breast adenocarcinoma).
Figure 2 Effect of the semi purified fraction F3 from Spongia
officinalis, on cellular growth against three human tumor cell
lines (A549, lung cell carcinoma, HCT15, colon cell carcinoma







Figure 3 The semi purified fraction F2 induced clonogenic
inhibition in human tumor cell lines (A549, lung cell carcinoma,
HCT15, colon cell carcinoma and MCF7, breast
adenocarcinoma).
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multiple comparison tests, to determine the significant
differences between a single control group mean and the
remaining treatment group means in an analysis of vari-
ance setting.Results
Evaluation of anti-inflammatory activity
Results of the carrageenan induced rat paw edema are
shown in Table 1. The i.p. administration of the
methanol extract of Spongia officinalis (25, 50 and
100 mg/kg) produced a significant reduction of the
edema throughout the entire period of observation in a
dose related manner. Interestingly the highest reduction
of the edema was at 3 h with respectively 42.5, 52.7 and
61.71%. After i.p. administration of the semi-purified
fractions F2 and F3 obtained by fractionation of the
methanol extract, significant activity was observed with
fraction F3 at the dose of 50 mg/kg, at the third hour
after carrageenan injection, with 72.85% reduction in
paw volume, whereas at the same time, F2 inhibited
edema by 58.05. Standard drugs, ASL (300 mg/kg),
decreased paw edema by 62.3% at the third hour
(Table 1). The present results indicate that methanolTable 3 In vitro colony inhibitory activity of the semi-
purified fractions, F2 and F3, of Spongia officinalis against
three human tumor cell lines: A549 (lung cell carcinoma),
HCT15 (colon cell carcinoma) and MCF7 (breast
adenocarcinoma)
IC50 (μg/ml)
Fractions A549 HCT15 MCF7
F2 fraction 875 - 375
F3 fraction 137.5 139.25 37.5
IC50: 50 percent inhibition of colony formationextract and its semi-purified fractions exhibit anti-in-
flammatory effects.
Evaluation of antiproliferative activity against tumor cell
lines
In the first experiment, F2 was tested for its effect on in-
hibition of cell growth against three human tumor cell
lines A549, HCT15 and MCF7 over a concentration
range (100–2000 μg/ml) to determine their potency
(IC50-50% inhibition of cell growth), results are shown in
Table 2. Assay was performed in vitro on exponentially
growing cells. The activity was evaluated by measuring
the levels of surviving cell after incubation for 24 h with
the test samples, using the MTT colorimetric assay
[15,17]. This is the first step in our anticancer drug de-
velopment program and is designed to identify those
extracts with cytotoxic activity. The results of this
primary screening are reported in Figure 1. F2 exhibited
a rather moderate cytotoxicity. 50% inhibition of cell







Figure 4 The semi purified fraction F3 induced clonogenic
inhibition in human tumor cell lines (A549, lung cell carcinoma,
HCT15, colon cell carcinoma and MCF7, breast
adenocarcinoma).
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A549 and MCF7. However within the series studied, F3
revealed a significant activity against A549, HCT15 and
MCF7 cell lines at concentration related manner
(25–500 μg/ml), the results are shown in Figure 2. 50%
inhibition of cell growth was obtained at concentrations
of 231, 212.5 and 72 μg/ml respectively against human
tumor cell lines tested A549, HCT15 and MCF7
(Table 2). Since the inhibitory effects of F2 and F3 on the
inhibition of cell growth using the MTT colorimetric
assay were established, we then examined their effects
on cell viability by clonogenic inhibition assay against
the same three human tumor cell lines (A549, HCT15
and MCF7) with the same range of concentrations. The
latter allows the chemosensitivity study but is more time
consuming than the other [18]. Results of this assay are
presented in Table 3. In our experiments, data for anti-
proliferative effect of F2 on A549 and MCF7 cells
showed a significant clonogenic inhibition at concentra-
tion-related manner, results are reported in Figure 3.
50% inhibition of cell growth was obtained at concentra-
tions of 875 and 375 μg/ml respectively against human
tumor cell lines tested A549 and MCF7 (Table 3). In a
further experiment, F3 produced significant clonogenic
inhibition too (Figure 4). IC50 are 137.5, 139.25 and
37.5 μg/ml respectively against human tumor cell lines
tested A549, HCT15 and MCF7 (Table 3).
Both F2 and F3 semi-purified fractions of Spongia offi-
cinalis showed, in vitro, significant antiproliferative activ-
ities. The IC50 values clearly indicated that the semi-
purified fraction F3 had a much more potent effect, on
the three human tumor cell lines tested, than F2. In term
of cell line sensitivity, different responses were observed
against the three human tumor cell lines, and no effect
was observed on HCT15 cells with the semi purified F2.
Discussion
Carrageenan rat paw edema assay is one of the most
commonly used assays to assess anti-inflammatory activ-
ity of marine natural products from sponges [10,19]. Car-
rageenan rat paw edema test produced an acute
inflammation that results from the sequential action of
several mediators. Histamine and serotonin were mainly
released during first 1.5 h after carrageenan injection,
kinin was released until 2.5 h and at the last step inflam-
mation was continued until 5 h by prostaglandins
[20-22]. The anti-inflammatory activity of the methanol
extract and its semi-purified fractions suggest that they
could interfere with some of the mediators, by inhibiting
their productions or antagonize their actions. Anti-
inflammatory drugs such as aspirin and other NSAIDs
act by downregulating prostanoids synthesis. Prostanoids
are potent biologically active arachidonic acid derived
lipid mediators that are intimately involved in inflammationand cancer [23]. In addition to their anti-inflammatory ac-
tivity, Spongia have also cytotoxic properties. Related agents,
such as macrolide [24], furanoditerpene [25], polyketide
[26], alkaloid, sesterterpene, triterpene, furanoterpene
[10,27,28], diterpene [29], sesquiterpene and nucleoside
[30], have already been isolated from other species of the
genus Spongia.
The functional tests to predict the response of tumors
to cytotoxic drugs comprise the MTT reduction and clo-
nogenic assay. The MTT colorimetric assay [15,17] is
based on the ability of metabolically active cells to con-
vert the pale yellow MTT to a blue formazan product,
which is quantifiable spectrophotometrically and the clo-
nogenic assay or colony formation assay is an in vitro
cell survival assay based on the ability of a single cell to
grow into a colony. The colony is defined to consist of at
least 50 cells. This clonogenic assay has been used in the
ensuing decades for a large variety of studies with many
types of cells. The assay detect all cells that have retained
the capacity for producing a large number of progeny
after treatments that can cause cell reproductive death as
a result of damage to chromosomes, apoptosis [31].
In the current study, both F2 and F3 fractions of the
Mediterranean sponge, Spongia officinalis showed,
in vitro, a significant antiproliferative activity against
three human cancer cell lines A549, HCT15 and MCF7.
The IC50 values clearly indicated that the semi-purified
fraction F3 had a much more potent effect on the three
human tumor cell lines than F2 and should be tested on
several other cancer cell lines.
All these findings support the need for further investi-
gations to clarify the features underlying the anti-inflam-
matory and the antiproliferative potential of these
fractions. Biochemical and molecular studies carried out
using the fraction in different animal models to establish
their therapeutic efficacy, and subjected to HPLC and
LC&MS analyses to identify and characterize the effica-
cious bioactive compound(s) in Spongia officinalis.
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